Scientific Online Resource System

Annual for Hospital Pharmacy

Review Of Systemic Approaches And Adjuvant Therapy In The Treatment Of Resectable Colorectal Cancer In Adult Patients

Krum Kafedjiiski

Abstract

Colorectal cancer continues to present a serious problem for the modern medicine and in particular regarding the treatment of older patients. Specific difficulties are described for the treatment of this population. The adjuvant chemotherapy for the treatment of stage II and III resectable colorectal cancer is analyzed. The safety and efficacy of the adjuvant chemotherapy as well as the specific difficulties for the treatment of these patients are also reviewed. The life expectancy in years depending on the age during diagnosis and also the number of concurrent chronic diseases are assessed. The latest data are summarized, which recommend the routine use of adjuvant chemotherapy in more fit patients with stage III and high-risk stage II cancer. It is also outlined that older patients with significant functional impairments are not suitable candidates for adjuvant chemotherapy.

Keywords

colorectal cancer, overall survival, fluoropyrimidines, adjuvant chemotherapy

Full Text


References

Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, Li X. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15:95.

The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer. Version 3.2021, (2021)

The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. Version 2.2021, (2021)

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, (2016)

Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. CA Cancer J Clin. 2015;7:153–69.

O’Sullivan B, Brierley JD, D’Cruz A, Fey M, Pollock R, Vermorken J, Huang S. UICC Manual of Clinical Oncology, Ninth Edition, 2015, ISBN: 978-1-444-33244-5

O‘Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381-88.

Веков Т, Лебанова Х, Григоров Е. Целеви онкологични терапии, базирани на моноколонални антитела – фармакоикономически оценки и приложението им в България. Обща медицина. 2015;17(3):17-26.

Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-34.

Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know? Cancer. 1994;74:1995-2003.

Hristov E, Ognyanov S, Deliyski T, Andreevska K, Burgazliev H, Grekova D, Dimitrova Z, Yordanov E, Rashkov D. Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions in Bulgaria. J Adv Res Pharm Sci Pharmacol Interv. 2019;2(2):1-6.

Gross C, McAvay G, Krumholz H, Paltiel AD, Bhasin D, Tinetti ME. The Effect of Age and Chronic Illness on Life Expectancy after a Diagnosis of Colorectal Cancer: Implications for Screening. Ann Int Med. 2006;145:646-53.

Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109(12):2410.

Веков Т, Колев Ж. Модел за реимбурсиране чрез рефериране на цените на целевите онкологични терапии за лечение на метастазирал колоректален карцином, основано на оценка на здравните технологии в България, 2017 г. Медицински мениджмънт и здравна политика. 2017;51(3):3-16.




DOI: http://dx.doi.org/10.14748/ahp.v8i1.8633

Refbacks

Article Tools
Email this article (Login required)
|